Vor Biopharma Inc.
VORNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$371.6M | −$121.2M | −$126.0M | −$93.4M | −$69.0M | −$43.4M |
| Net income | −$696.0M | −$116.9M | −$117.9M | −$92.1M | −$68.9M | −$43.3M |
| Total assets | $464.1M | $142.9M | $198.1M | $299.4M | $242.6M | $75.9M |
| Total liabilities | $628.4M | $46.2M | $47.4M | $48.8M | $26.3M | $27.6M |
| Equity | −$164.3M | $96.7M | $150.7M | $250.6M | $216.3M | −$59.1M |
| EPS (diluted) | $-70.50 | $-34.03 | $-1.75 | $-2.33 | $-2.10 | — |
| Shares out. | 124.9M | 68.2M | 66.4M | 37.5M | 37.2M | 505,074 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- 423.6%
- Return on assets
- −150.0%
- Return on capital (ROCE)
- −84.7%
- Liabilities / assets
- 135.4%
- Debt / equity
- —
- Book value / share
- $-1.32
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -7.63distress
- Accruals / assets
- −119.2%clean
- Piotroski F-Score
- 2/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 2 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Recruitingreadout ~2027-05A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
- Phase 3Recruitingreadout ~2028-12Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Verve Capital LtdPassive (13G)May 15, 2026
- Venrock Healthcare Capital Partners Iii, L.P.Passive (13G)May 15, 2026
- Qiming Venture Partners Viii-Hc, L.P.Passive (13G)May 6, 2026
- Fmr LlcPassive (13G)May 6, 2026
- Ra Capital Management, L.P.Activist (13D)Apr 21, 2026
- Tcg Crossover Gp Ii, LlcPassive (13G)Apr 1, 2026
- Great Point Partners LlcPassive (13G)Feb 17, 2026
- Paradigm Biocapital Advisors LpPassive (13G)Feb 17, 2026
- Forgrowth Iii Pa B.V.Activist (13D)Dec 23, 2025
- Frazier Life Sciences Public Fund, L.P.Passive (13G)Dec 19, 2025
- Reprogrammed Interchange LlcActivist (13D)Oct 17, 2025
- 5am Ventures Vi, L.P.Activist (13D)Jul 9, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Ra Capital Management, L.P.Director | Apr 22, 2026 | Sell | 165,150 | $15.77 |
| Ra Capital Management, L.P.Director | Apr 17, 2026 | Sell | 458,411 | $16.28 |
| Ra Capital Management, L.P.Director | Apr 13, 2026 | Sell | 530,610 | $16.15 |
| Ra Capital Management, L.P.Director | Apr 8, 2026 | Sell | 353,242 | $16.32 |
| Ra Capital Management, L.P.Director | Apr 2, 2026 | Sell | 258,475 | $18.23 |
| Ra Capital Management, L.P.Director | Dec 18, 2025 | Grant | 4.6M | $10.81 |
| Mahatme SandeshOfficer — CFO | Dec 5, 2025 | D | 694,137 | $0.00 |
| Ra Capital Management, L.P.Director | Oct 28, 2025 | Sell | 87,828 | $27.10 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 4.6M | 5.3 | -7.3% |
| Apr 30, 2026 | 5.0M | 5.1 | +5.3% |
| Apr 15, 2026 | 4.7M | 3.5 | -17.3% |
| Mar 31, 2026 | 5.7M | 4.1 | +66.5% |
| Mar 13, 2026 | 3.4M | 5.6 | +0.9% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Unregistered equity sale · Regulation FD disclosureMar 27, 2026
- Results of operations · Regulation FD disclosureJan 12, 2026
- Director / officer changeJan 2, 2026
- Entered a material agreement · Unregistered equity sale · Director / officer change · Regulation FD disclosureDec 18, 2025
- Director / officer changeDec 9, 2025
- Other material eventNov 12, 2025
- Director / officer change · Regulation FD disclosureNov 3, 2025
- Regulation FD disclosureOct 28, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13G/AMay 15, 2026
- 10-QMay 13, 2026
- EFFECTMay 6, 2026
- SCHEDULE 13G/AMay 6, 2026
- SCHEDULE 13G/AMay 6, 2026
- S-3Apr 27, 2026
- ARSApr 27, 2026
- DEFA14AApr 27, 2026
- DEF 14AApr 27, 2026
- 4Apr 24, 2026
- SCHEDULE 13D/AApr 21, 2026
- 4Apr 21, 2026
- SCHEDULE 13D/AApr 15, 2026
- 4Apr 15, 2026
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.